Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer's latest pipeline refinement shows the drug maker is more than willing to stick with its professed "invest to win" core therapeutic areas after acquiring Wyeth, but the pharma giant is, nonetheless, hedging its bets by keeping some compounds from other areas for the sake of diversity

You may also be interested in...



"The Pink Sheet" – Most Notable Stories Of 2010

While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.

"The Pink Sheet" – Most Notable Stories Of 2010

While industry mega-mergers occupied readers in 2009, the focus in 2010 shifted toward several evolving policy concerns and their impact on company strategy. Among these, more companies are looking at the opportunity for biosimilars created by the health care reform law's provision of a legal framework for product approval. But early analyses suggest that there is still a lot of work to do as FDA develops a guideline for industry on an abbreviated approval pathway.

In Another Pfizer Fire Sale, VC-Backed Conatus Acquires Idun's Idle Assets

Launched in 2006 by Idun's former management team, San Diego startup Conatus buys back a familiar property at a rock-bottom price.

Related Content

Topics

UsernamePublicRestriction

Register

PS051895

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel